IGF-1 DES: What It Is and What the Research Shows

At a glance

What is IGF-1 DES?

IGF-1 DES (short for DES(1-3) IGF-1) is a modified version of insulin-like growth factor-1, missing its first three amino acids. That truncation reduces how tightly it binds the proteins that normally hold IGF-1 in check, making it more potent in laboratory systems. It is sold as a "research chemical" and used as a performance-enhancing drug for muscle growth; it is not an approved medicine.

How does it work?

IGF-1 DES acts on the IGF-1 receptor, the pathway that drives muscle protein synthesis and tissue growth. Because it is less bound by carrier proteins, it is proposed to have higher local activity than natural IGF-1. In rodents it improved nitrogen balance and reduced muscle protein breakdown, and it is used in cell culture as a high-potency growth stimulus. These are animal and laboratory findings. This describes the proposed mechanism, separate from proven outcomes in people. (A different, full-length IGF-1 product, mecasermin, is an approved drug for a rare growth disorder; IGF-1 DES is a separate, unapproved analog.)

Is it FDA-approved?

No. IGF-1 DES is not approved by the FDA; it functions as a research chemical and performance-enhancing drug with no approved compounding status. In sport, IGF-1 and its analogs are prohibited at all times under the WADA list.

What does the research show?

The evidence is preclinical. According to PubMed, an animal study reported improved nitrogen balance and reduced protein breakdown, and the peptide is a standard high-potency reagent in cell-growth assays. There are no human clinical trials supporting muscle or performance use, so its marketed benefit is unproven in people.

Evidence strength

Low research: There is no human efficacy evidence; the muscle-growth rationale rests entirely on animal and cell studies.

Sources: an animal study of IGF-1 and protein metabolism (Martin et al., American Journal of Physiology, 1991, DOI: 10.1152/ajprenal.1991.261.4.F626) and a review of performance peptides (Dominikowski et al., Frontiers in Endocrinology, 2026, DOI: 10.3389/fendo.2026.1822475), indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.